Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein–coupled estrogen receptor 1 (GPER) is a non-classical estrogen receptor, structurally belonging to the G protein–coupled receptor superfamily[1][3][5][7][9]. It is primarily localized to the endoplasmic reticulum and intracellular membranes but can also be found at the plasma membrane[7]. GPER is activated by estradiol and mediates rapid, non-genomic signaling events, including transactivation of epidermal growth factor receptor (EGFR), stimulation of cell proliferative pathways, and anti-apoptotic signaling[2][7][9]. Unlike classical estrogen receptors (ERα and ERβ), which function as nuclear transcription factors, GPER operates through G protein–dependent mechanisms to regulate intracellular cAMP, protein kinase A (PKA), and other downstream kinases such as PI3K/Akt and ERK[7][9]. GPER plays roles in reproductive tissues, the cardiovascular system, metabolism, and the central nervous system[4][5][6][8]. Its expression and activity are implicated in various diseases, notably cancers of the reproductive system, metabolic syndrome, cardiovascular disease, and some neurological conditions[2][4][6][8]. Therapeutically, both agonists and antagonists targeting GPER are under investigation for their potential in oncology, metabolic disorders, and cardiovascular diseases. Endocrine-modulating drugs like Tamoxifen and Fulvestrant, although traditionally considered antagonists of nuclear estrogen receptors, act as agonists at GPER, influencing drug responsiveness and resistance[8]. GPER expression is a prognostic marker in several cancers, and its modulation presents both opportunities and risks in disease therapy, particularly where rapid estrogen signaling contributes to pathology[2][8].
Agonists: Activate rapid, non-genomic cell signaling via GPER (increase cAMP, activate EGFR, stimulate PI3K/Akt, ERK, promote cell proliferation, survival, metabolic regulation) Antagonists: Block estrogen-induced rapid signaling, may inhibit cancer cell proliferation or prevent metabolic effects
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein–coupled estrogen receptor 1 (GPER).